Dec 07, 2014
From the Healthcare & Life Sciences Institute
In an increasingly convergent healthcare ecosystem, life sciences companies and providers often depend on each other, especially in regard to the accuracy of aggregate spend reporting data. Pharmaceutical, biotech, and medical device manufacturers conduct assessments of their aggregate spend compliance programs to confirm they are performing as intended. However, the typical assessment merely skims the surface—focusing primarily on interviews and document reviews rather than on the underlying data. As a result, errors and omissions are missed, leaving manufacturers—and, by extension, providers—exposed to the unnecessary risk of noncompliance.